Abstract

Background

Carotid endarterectomy and carotid artery stenting are common procedures for the treatment of carotid artery stenosis. The aim of this study was to identify factors that modify the effect between type of treatment and outcome, and could thus be used to refine the selection of treatment procedure.

Methods

All patients who underwent either carotid endarterectomy or carotid artery stenting between 2012 and 2018 in German hospitals were included. The analysis of effect modification was focused on baseline patient characteristics. The outcome was a composite of any stroke or death until discharge from hospital. For multivariable analyses, a generalized linear mixed regression model was used.

Results

Some 221 282 patients were included, of whom 68% were male. In patients who underwent carotid endarterectomy or carotid artery stenting, the risk of any stroke or death was 2.3% and 3.7% respectively. Patient age was statistically significantly associated with a higher risk of a composite outcome of any stroke or death (main effect of age: adjusted OR 1.21 (95% c.i. 1.17 to 1.26), P < 0.001). The age effect was stronger in patients treated with carotid artery stenting (interaction effect: adjusted OR 1.29 (95% c.i. 1.20 to 1.38), P < 0.001). Statistically significant interaction effects were identified for side of treatment, ASA grade, contralateral degree of stenosis, and the time interval between the index event and treatment.

Conclusion

This analysis shows that carotid artery stenting may be particularly disadvantageous in older patients, in patients with right-sided stenosis, and in symptomatic patients treated within the first 2 days after the index event. In patients with contralateral occlusion, carotid artery stenting appears equivalent to carotid endarterectomy.

Lay Summary

The internal carotid artery supplies the brain with blood from both sides of the neck. The vessel can be narrowed due to a thickened and sick wall. This increases the risk of a brain stroke. To treat this narrowing, a surgical approach that involves peeling out the diseased wall parts can be performed. A less invasive approach that involves covering with a stent is also possible. The treatment is done to lower the risk of a stroke or other bad events, such as death. The treatment itself can also trigger these events. In German hospitals every treatment of the carotid artery is recorded in a central database. This study uses a statistical method involving almost all the data from this database. The years 2012 to 2018 were covered. The authors try to find factors that improve the choice of therapy method. The analysis shows that older patients and patients with right-sided disease have a higher risk when treated with stenting. This also applies to patients who are treated within 2 days after warning symptoms. Patients with contralateral occlusion may benefit from both methods.

Introduction

Carotid endarterectomy (CEA) and carotid artery stenting (CAS) are the predominant procedures used for treating carotid artery stenosis. Therapy indications, diagnostic measures, and treatment types need to be established under international guideline recommendations1–3. In general, CEA is the standard therapy, whereas CAS may be considered an alternative in selected patients4, especially symptomatic patients at high surgical risk1. Regarding the choice of procedure (CEA or CAS), the decision should be based on patient-specific clinical and morphological variables, as well as the patient’s personal preferences (level of evidence/grading of recommendation: expert consensus, German–Austrian guideline1). The following characteristics and morphological variables are associated with higher risk when performing CAS (making CEA more beneficial): older age (greater than 70 years), a short time interval between the index event and treatment, difficult access for CAS, and morphological characteristics of long stenosis, heavy calcification, vessel elongation, and plaque ulceration (expert consensus based on Naylor et al.2 and Aboyans et al.5). In contrast, the following characteristics are associated with higher risk when performing CEA: restenosis, post-radiation stenosis, skull base near stenosis, tandem stenosis, and contralateral paresis of the recurrent laryngeal nerve (expert consensus1). However, all grades of the latter recommendations are expert consensus only, as higher-level evidence, for example direct head-to-head randomized studies, which justifies a higher grade of recommendation, remains unavailable. Regarding transfemoral CAS, a risk-calculating tool for the 30-day risk of stroke or death was developed based on a secondary data analysis of the Vascular Quality Initiative database6. This analysis directly associated the following factors with a higher risk in patients treated with CAS: age, race, diabetes, coronary artery disease, chronic heart failure, symptomatic status, and contralateral occlusion. In contrast, dual antiplatelet therapy and statin use were related to lower risk after CAS. Notably, these risk prediction models conducted the analysis either within a CEA or within a CAS cohort, but not simultaneously in both6,7.

The aim of this study was to identify factors that modify the effect between treatment types and outcomes, which can be used to refine the selection process of treatment type.

Methods

This was a pre-planned substudy analysis of the ISAR-IQ project (Integration and Spatial Analysis of Regional, site-specific, and patient-level factors for Improving the Quality of treatment for carotid artery stenosis).

Data source

This study was based on the nationwide German statutory quality assurance measures according to § 136 SGB V of the Federal Joint Committee operated by the Institute for Quality Assurance and Transparency in Healthcare (Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG)). The IQTIG statutorily collected data on carotid revascularization procedures (CEA and CAS) in all German hospitals. Data were collected for all CEA and CAS procedures, except for those performed at military hospitals and outpatient clinics, because of legal obligations. The Ethics Committee of the Medical Faculty, Technical University of Munich approved this study (Reference Number 107/20S). The analysis was conducted in accordance with the Good Practice of Secondary Data Analysis guidelines8. REporting of studies Conducted using Observational Routinely-collected Data (RECORD) reporting guidelines were applied; this was appropriate because this was an observational study using routinely collected health data9. All data were saved on IQTIG servers, following the respective data protection regulations. Controlled remote data processing was used to permit data access. The ISAR-IQ study protocol was submitted to the IQTIG and the Gemeinsamer Bundesausschuss, Germany’s Federal Joint Committee (G-BA) during the application procedure, but was not published separately. Further details on methods have already been published1,10–21.

Inclusion and exclusion criteria

This study included all patients who underwent either CEA or CAS for carotid stenosis (asymptomatic, symptomatic, emergency, and other indications) from 2012 to 2018 in German hospitals (Fig. 1). Patients who underwent procedures other than CEA/CAS, as well as patients who underwent combined/converted procedures, patients who underwent combined carotid-coronary or carotid-peripheral artery procedures, and patients who underwent CAS procedures to primarily gain access for an intracranial intervention were excluded; in addition, patients with unknown or diverse sex were excluded. The latter was required to avoid extensive output blocking due to data protection issues. Patients were categorized as asymptomatic, symptomatic, or others. Symptomatic patients were subcategorized as symptomatic ‘elective’ (amaurosis fugax, transient ischaemic attack (TIA), stroke, or other elective symptoms) or symptomatic ‘emergency’ (crescendo TIA, stroke-in-evolution, or other emergency symptoms) based on the urgency of the care provided. In total, 221 282 patients were finally included.

Patient flow chart illustrating inclusion and exclusion criteria
Fig. 1

Patient flow chart illustrating inclusion and exclusion criteria

*Excluding combined/converted procedures (CAS and CEA) and CAS procedures performed for the primary purpose of gaining access for an intracranial intervention. Special conditions include simultaneous cardiac, aortic, or peripheral vascular surgical procedures. CEA, carotid endarterectomy; CAS, carotid artery stenting.

Grouping variables and outcome

The patients were mainly categorized based on the procedure they underwent (CEA versus CAS as a comparative variable) and the occurrence of the outcome event (OE). The OE was the compound endpoint of ‘any stroke or death’, which is used in many major studies and guidelines and is crucial for the patient1,2,5. This endpoint refers to the interval up to discharge from the hospital, as the statutory quality assurance system recorded no data after discharge.

Statistical analyses

Categorical variables are presented as n (%) and continuous variables are presented as median (interquartile range).

R function ‘glmer’ with logit link function was used for multilevel multivariable regression analysis. The pre-procedural and post-procedural neurological-clinical assessments were included in the model as fixed effects by default because they were the strongest confounders in all previous analyses.

The procedure type (CEA versus CAS) was included as a fixed effect, as were the clinical variables age, sex, ASA grade, side of treatment, ipsilateral degree of stenosis, contralateral degree of stenosis, type of index event (initial neurological symptoms), time interval between the index event and treatment (only for electively treated symptomatic patients), morphological characteristics (for example ulcerated plaques and aneurysmal changes in addition to the stenosis), and centre annual caseload. The models involved an interaction term between the form of therapy and the respective clinical variable.

Hospital identifier and year of treatment were entered as random factors into the model (intercept only) to adjust for clustering effects and temporal trends respectively22–24.

The chi-squared test was used to analyse differences regarding intra- and post-procedural variables. R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria) was utilized for data processing and statistical analysis, with extension packages ‘tidyverse’, ‘epitools’, ‘lme4’, ‘expss’, and ‘ggplot2’ used for cross-classified tables, chi-squared tests, and multivariable regression analyses.

Scatter plots with individual patient data points must not be created for data protection reasons. The differential effects of age and hospital caseload were visualized using microsimulation (n = 10 000) based on the parameters calculated by the abovementioned multivariable regression models for an easily understandable graphical depiction of interaction effects. Graphic processing of the data was conducted using Microsoft Excel. A two-tailed level of significance of α = 5% was used for all tests. For further details on the statistical methods please see the Supplementary material.

Results

Characteristics of patients

This study included 221 282 patients, of whom 68% were male. Of the patients, 179 724 (81%) and 41 558 (19%) underwent CEA and CAS respectively. The majority of patients were asymptomatic (55%). Table 1 shows details on baseline characteristics of patients on hospital admission. Among patients who underwent CEA, general anaesthesia was predominantly used (71%), followed by local anaesthesia (27%) and combined/modified measures (2.5%). Revascularization success was controlled by intraoperative completion study in 74% of patients; imaging techniques, such as angiography or ultrasonography, were used in 56% of patients. Table 2 shows details on perioperative and intraoperative management.

Table 1

Baseline characteristics of patients on hospital admission by type of treatment, primary outcome event, and raw risks

Clinical variableOverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Patients221 282 (100)4099 (1.9)1524 (0.7)175 625 (79)40 034 (18)<0.001
Age (years), median (interquartile range)72 (64–77)74 (67–79)75 (67–80)72 (65–78)70 (63–77)
Sex
 Male150 734 (68)2768 (68)1020 (67)119200 (68)27 746 (69)<0.001
 Female70 548 (32)1331 (32)504 (33)56 425 (32)12 288 (31)<0.001
Side of treatment
 Right110 910 (50)1780 (43)703 (46)88 610 (51)19 817 (50)<0.001
 Left110 372 (50)2319 (57)821 (54)87 015 (49)20 217 (50)<0.001
ASA grade*
 I/II72 169 (33)614 (15)538 (36)48 211 (28)22 806 (59)<0.001
 III139 822 (64)3022 (74)649 (43)121 591 (70)14 560 (38)<0.001
 IV/V7206 (3.3)449 (11)314 (21)5027 (2.9)1416 (3.7)<0.001
Ipsilateral degree of stenosis†
 Mild (<50%)3753 (1.7)132 (3.2)53 (3.5)2599 (1.5)969 (2.4)0.657
 Moderate (50–69%)11 400 (5.2)286 (7.0)95 (6.2)8839 (5.0)2180 (5.5)0.013
 Severe (70–99%)203 025 (92)3551 (87)1123 (74)162 972 (93)35 379 (88)<0.001
 Occlusion (100%)3104 (1.4)130 (3.2)253 (17)1215 (0.7)1506 (3.8)<0.001
Contralateral degree of stenosis†
 Mild (<50%)150 898 (68)2525 (62)1075 (71)119 068 (68)28 230 (71)<0.001
 Moderate (50–69%)30 507 (14)606 (15)116 (7.6)25 848 (15)3937 (9.8)0.026
 Severe (70–99%)26 022 (12)557 (14)180 (12)21 070 (12)4215 (11)<0.001
 Occlusion (100%)13 855 (6.3)411 (10)153 (10)9639 (5.5)3652 (9.1)0.855
Neurological symptoms
 Asymptomatic122 363 (55)1461 (36)374 (25)99 454 (57)21 074 (53)0.001
 Amaurosis fugax12 375 (5.6)140 (3.4)24 (1.6)10 374 (5.9)1837 (4.6)0.884
 TIA23 257 (11)481 (12)107 (7.0)19 718 (11)2951 (7.4)<0.001
 Stroke (minor/major/NA)39 571 (18)1137 (28)326 (21)31 249 (18)6859 (17)<0.001
 Other elective symptoms3764 (1.7)80 (2.0)28 (1.8)2673 (1.5)983 (2.5)0.824
 cTIA/SIE9962 (4.5)414 (10)417 (27)5662 (3.2)3469 (8.7)<0.001
 Other emergency symptoms9990 (4.5)386 (9.4)248 (16)6495 (3.7)2861 (7.1)<0.001
Time interval (days)‡
 0–28023 (11)260 (15)104 (23)6152 (11)1507 (13)<0.001
 3–727 323 (38)652 (38)149 (32)22 723 (39)3799 (33)<0.001
 8–1415 169 (21)381 (22)71 (15)12 393 (21)2324 (20)0.962
 15–18021 920 (30)443 (26)137 (30)17 564 (30)3776 (33)<0.001
Morphological characteristics§
 Ulcerated plaque22 276 (10)591 (14)96 (6.3)19 962 (11)1627 (4.1)<0.001
 Aneurysmal change¶1418 (0.6)68 (1.7)27 (1.8)891 (0.5)432 (1.1)0.394
 Coiling1648 (0.8)59 (1.4)13 (0.9)1449 (0.8)127 (0.3)<0.001
 Multiple lesions6354 (2.9)239 (5.8)211 (14)3634 (2.1)2270 (5.7)<0.001
Clinical variableOverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Patients221 282 (100)4099 (1.9)1524 (0.7)175 625 (79)40 034 (18)<0.001
Age (years), median (interquartile range)72 (64–77)74 (67–79)75 (67–80)72 (65–78)70 (63–77)
Sex
 Male150 734 (68)2768 (68)1020 (67)119200 (68)27 746 (69)<0.001
 Female70 548 (32)1331 (32)504 (33)56 425 (32)12 288 (31)<0.001
Side of treatment
 Right110 910 (50)1780 (43)703 (46)88 610 (51)19 817 (50)<0.001
 Left110 372 (50)2319 (57)821 (54)87 015 (49)20 217 (50)<0.001
ASA grade*
 I/II72 169 (33)614 (15)538 (36)48 211 (28)22 806 (59)<0.001
 III139 822 (64)3022 (74)649 (43)121 591 (70)14 560 (38)<0.001
 IV/V7206 (3.3)449 (11)314 (21)5027 (2.9)1416 (3.7)<0.001
Ipsilateral degree of stenosis†
 Mild (<50%)3753 (1.7)132 (3.2)53 (3.5)2599 (1.5)969 (2.4)0.657
 Moderate (50–69%)11 400 (5.2)286 (7.0)95 (6.2)8839 (5.0)2180 (5.5)0.013
 Severe (70–99%)203 025 (92)3551 (87)1123 (74)162 972 (93)35 379 (88)<0.001
 Occlusion (100%)3104 (1.4)130 (3.2)253 (17)1215 (0.7)1506 (3.8)<0.001
Contralateral degree of stenosis†
 Mild (<50%)150 898 (68)2525 (62)1075 (71)119 068 (68)28 230 (71)<0.001
 Moderate (50–69%)30 507 (14)606 (15)116 (7.6)25 848 (15)3937 (9.8)0.026
 Severe (70–99%)26 022 (12)557 (14)180 (12)21 070 (12)4215 (11)<0.001
 Occlusion (100%)13 855 (6.3)411 (10)153 (10)9639 (5.5)3652 (9.1)0.855
Neurological symptoms
 Asymptomatic122 363 (55)1461 (36)374 (25)99 454 (57)21 074 (53)0.001
 Amaurosis fugax12 375 (5.6)140 (3.4)24 (1.6)10 374 (5.9)1837 (4.6)0.884
 TIA23 257 (11)481 (12)107 (7.0)19 718 (11)2951 (7.4)<0.001
 Stroke (minor/major/NA)39 571 (18)1137 (28)326 (21)31 249 (18)6859 (17)<0.001
 Other elective symptoms3764 (1.7)80 (2.0)28 (1.8)2673 (1.5)983 (2.5)0.824
 cTIA/SIE9962 (4.5)414 (10)417 (27)5662 (3.2)3469 (8.7)<0.001
 Other emergency symptoms9990 (4.5)386 (9.4)248 (16)6495 (3.7)2861 (7.1)<0.001
Time interval (days)‡
 0–28023 (11)260 (15)104 (23)6152 (11)1507 (13)<0.001
 3–727 323 (38)652 (38)149 (32)22 723 (39)3799 (33)<0.001
 8–1415 169 (21)381 (22)71 (15)12 393 (21)2324 (20)0.962
 15–18021 920 (30)443 (26)137 (30)17 564 (30)3776 (33)<0.001
Morphological characteristics§
 Ulcerated plaque22 276 (10)591 (14)96 (6.3)19 962 (11)1627 (4.1)<0.001
 Aneurysmal change¶1418 (0.6)68 (1.7)27 (1.8)891 (0.5)432 (1.1)0.394
 Coiling1648 (0.8)59 (1.4)13 (0.9)1449 (0.8)127 (0.3)<0.001
 Multiple lesions6354 (2.9)239 (5.8)211 (14)3634 (2.1)2270 (5.7)<0.001

Values are n (%) unless otherwise indicated. *ASA grade missing for 2085 patients. †Degree of stenosis is in accordance with the North American Symptomatic Carotid Endarterectomy Trial (NASCET) standard. ‡Only available for symptomatic patients treated electively (not available for 148 847 patients). §Each yes versus no. ¶Aneurysmal change in addition to the atherosclerotic stenosis. OE, outcome event; CEA, carotid endarterectomy; CAS, carotid artery stenting; TIA, transient ischaemic attack; NA, information not available; cTIA, crescendo transient ischaemic attack; SIE, stroke-in-evolution.

Table 1

Baseline characteristics of patients on hospital admission by type of treatment, primary outcome event, and raw risks

Clinical variableOverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Patients221 282 (100)4099 (1.9)1524 (0.7)175 625 (79)40 034 (18)<0.001
Age (years), median (interquartile range)72 (64–77)74 (67–79)75 (67–80)72 (65–78)70 (63–77)
Sex
 Male150 734 (68)2768 (68)1020 (67)119200 (68)27 746 (69)<0.001
 Female70 548 (32)1331 (32)504 (33)56 425 (32)12 288 (31)<0.001
Side of treatment
 Right110 910 (50)1780 (43)703 (46)88 610 (51)19 817 (50)<0.001
 Left110 372 (50)2319 (57)821 (54)87 015 (49)20 217 (50)<0.001
ASA grade*
 I/II72 169 (33)614 (15)538 (36)48 211 (28)22 806 (59)<0.001
 III139 822 (64)3022 (74)649 (43)121 591 (70)14 560 (38)<0.001
 IV/V7206 (3.3)449 (11)314 (21)5027 (2.9)1416 (3.7)<0.001
Ipsilateral degree of stenosis†
 Mild (<50%)3753 (1.7)132 (3.2)53 (3.5)2599 (1.5)969 (2.4)0.657
 Moderate (50–69%)11 400 (5.2)286 (7.0)95 (6.2)8839 (5.0)2180 (5.5)0.013
 Severe (70–99%)203 025 (92)3551 (87)1123 (74)162 972 (93)35 379 (88)<0.001
 Occlusion (100%)3104 (1.4)130 (3.2)253 (17)1215 (0.7)1506 (3.8)<0.001
Contralateral degree of stenosis†
 Mild (<50%)150 898 (68)2525 (62)1075 (71)119 068 (68)28 230 (71)<0.001
 Moderate (50–69%)30 507 (14)606 (15)116 (7.6)25 848 (15)3937 (9.8)0.026
 Severe (70–99%)26 022 (12)557 (14)180 (12)21 070 (12)4215 (11)<0.001
 Occlusion (100%)13 855 (6.3)411 (10)153 (10)9639 (5.5)3652 (9.1)0.855
Neurological symptoms
 Asymptomatic122 363 (55)1461 (36)374 (25)99 454 (57)21 074 (53)0.001
 Amaurosis fugax12 375 (5.6)140 (3.4)24 (1.6)10 374 (5.9)1837 (4.6)0.884
 TIA23 257 (11)481 (12)107 (7.0)19 718 (11)2951 (7.4)<0.001
 Stroke (minor/major/NA)39 571 (18)1137 (28)326 (21)31 249 (18)6859 (17)<0.001
 Other elective symptoms3764 (1.7)80 (2.0)28 (1.8)2673 (1.5)983 (2.5)0.824
 cTIA/SIE9962 (4.5)414 (10)417 (27)5662 (3.2)3469 (8.7)<0.001
 Other emergency symptoms9990 (4.5)386 (9.4)248 (16)6495 (3.7)2861 (7.1)<0.001
Time interval (days)‡
 0–28023 (11)260 (15)104 (23)6152 (11)1507 (13)<0.001
 3–727 323 (38)652 (38)149 (32)22 723 (39)3799 (33)<0.001
 8–1415 169 (21)381 (22)71 (15)12 393 (21)2324 (20)0.962
 15–18021 920 (30)443 (26)137 (30)17 564 (30)3776 (33)<0.001
Morphological characteristics§
 Ulcerated plaque22 276 (10)591 (14)96 (6.3)19 962 (11)1627 (4.1)<0.001
 Aneurysmal change¶1418 (0.6)68 (1.7)27 (1.8)891 (0.5)432 (1.1)0.394
 Coiling1648 (0.8)59 (1.4)13 (0.9)1449 (0.8)127 (0.3)<0.001
 Multiple lesions6354 (2.9)239 (5.8)211 (14)3634 (2.1)2270 (5.7)<0.001
Clinical variableOverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Patients221 282 (100)4099 (1.9)1524 (0.7)175 625 (79)40 034 (18)<0.001
Age (years), median (interquartile range)72 (64–77)74 (67–79)75 (67–80)72 (65–78)70 (63–77)
Sex
 Male150 734 (68)2768 (68)1020 (67)119200 (68)27 746 (69)<0.001
 Female70 548 (32)1331 (32)504 (33)56 425 (32)12 288 (31)<0.001
Side of treatment
 Right110 910 (50)1780 (43)703 (46)88 610 (51)19 817 (50)<0.001
 Left110 372 (50)2319 (57)821 (54)87 015 (49)20 217 (50)<0.001
ASA grade*
 I/II72 169 (33)614 (15)538 (36)48 211 (28)22 806 (59)<0.001
 III139 822 (64)3022 (74)649 (43)121 591 (70)14 560 (38)<0.001
 IV/V7206 (3.3)449 (11)314 (21)5027 (2.9)1416 (3.7)<0.001
Ipsilateral degree of stenosis†
 Mild (<50%)3753 (1.7)132 (3.2)53 (3.5)2599 (1.5)969 (2.4)0.657
 Moderate (50–69%)11 400 (5.2)286 (7.0)95 (6.2)8839 (5.0)2180 (5.5)0.013
 Severe (70–99%)203 025 (92)3551 (87)1123 (74)162 972 (93)35 379 (88)<0.001
 Occlusion (100%)3104 (1.4)130 (3.2)253 (17)1215 (0.7)1506 (3.8)<0.001
Contralateral degree of stenosis†
 Mild (<50%)150 898 (68)2525 (62)1075 (71)119 068 (68)28 230 (71)<0.001
 Moderate (50–69%)30 507 (14)606 (15)116 (7.6)25 848 (15)3937 (9.8)0.026
 Severe (70–99%)26 022 (12)557 (14)180 (12)21 070 (12)4215 (11)<0.001
 Occlusion (100%)13 855 (6.3)411 (10)153 (10)9639 (5.5)3652 (9.1)0.855
Neurological symptoms
 Asymptomatic122 363 (55)1461 (36)374 (25)99 454 (57)21 074 (53)0.001
 Amaurosis fugax12 375 (5.6)140 (3.4)24 (1.6)10 374 (5.9)1837 (4.6)0.884
 TIA23 257 (11)481 (12)107 (7.0)19 718 (11)2951 (7.4)<0.001
 Stroke (minor/major/NA)39 571 (18)1137 (28)326 (21)31 249 (18)6859 (17)<0.001
 Other elective symptoms3764 (1.7)80 (2.0)28 (1.8)2673 (1.5)983 (2.5)0.824
 cTIA/SIE9962 (4.5)414 (10)417 (27)5662 (3.2)3469 (8.7)<0.001
 Other emergency symptoms9990 (4.5)386 (9.4)248 (16)6495 (3.7)2861 (7.1)<0.001
Time interval (days)‡
 0–28023 (11)260 (15)104 (23)6152 (11)1507 (13)<0.001
 3–727 323 (38)652 (38)149 (32)22 723 (39)3799 (33)<0.001
 8–1415 169 (21)381 (22)71 (15)12 393 (21)2324 (20)0.962
 15–18021 920 (30)443 (26)137 (30)17 564 (30)3776 (33)<0.001
Morphological characteristics§
 Ulcerated plaque22 276 (10)591 (14)96 (6.3)19 962 (11)1627 (4.1)<0.001
 Aneurysmal change¶1418 (0.6)68 (1.7)27 (1.8)891 (0.5)432 (1.1)0.394
 Coiling1648 (0.8)59 (1.4)13 (0.9)1449 (0.8)127 (0.3)<0.001
 Multiple lesions6354 (2.9)239 (5.8)211 (14)3634 (2.1)2270 (5.7)<0.001

Values are n (%) unless otherwise indicated. *ASA grade missing for 2085 patients. †Degree of stenosis is in accordance with the North American Symptomatic Carotid Endarterectomy Trial (NASCET) standard. ‡Only available for symptomatic patients treated electively (not available for 148 847 patients). §Each yes versus no. ¶Aneurysmal change in addition to the atherosclerotic stenosis. OE, outcome event; CEA, carotid endarterectomy; CAS, carotid artery stenting; TIA, transient ischaemic attack; NA, information not available; cTIA, crescendo transient ischaemic attack; SIE, stroke-in-evolution.

Table 2

Perioperative and intraoperative management

OverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Neurological assessment*
 Pre-procedural161 069 (73)3211 (78)1341 (88)124 088 (71)32 429 (81)<0.001
 Post-procedural138 556 (63)3469 (85)1393 (91)104 419 (60)29 275 (73)<0.001
 Pre- and post-procedural128 510 (58)2914 (71)1289 (85)96 118 (55)28 189 (70)<0.001
Preoperative diagnostic procedures*†‡
 Duplex ultrasonography152 681 (96)2784 (97)702 (71)124 661 (98)24 534 (88)<0.001
 Transcranial Doppler45 833 (29)956 (33)415 (42)34 348 (27)10 114 (36)<0.001
 CT angiography83 861 (53)1899 (66)681 (69)66 739 (53)14 542 (52)<0.001
 MRI angiography74 976 (47)1301 (45)419 (42)60 729 (48)12 527 (45)<0.001
Perioperative antiplatelet medication
 None13 361 (6.0)332 (8.1)148 (9.7)11 577 (6.6)1304 (3.3)<0.001
 ASS monotherapy163 612 (74)3464 (85)477 (31)149 984 (85)9687 (24)<0.001
 Clopidogrel monotherapy5781 (2.6)94 (2.3)53 (3.5)4392 (2.5)1242 (3.1)<0.001
 Other monotherapy1078 (0.5)8 (0.2)33 (2.2)767 (0.4)270 (0.7)<0.001
 Dual antiplatelet medication37 450 (17)201 (4.9)813 (53)8905 (5.1)27 531 (69)0.001
Type of anaesthesia‡
 Local34 775 (27)589 (21)34 186 (27)
 General91 562 (71)2194 (76)89 368 (71)
 Combined§3265 (2.5)97 (3.4)3168 (2.5)
Intra-procedural monitoring‡¶
 Electroencephalography8209 (5.2)149 (5.2)8 (0.8)7903 (6.2)149 (0.5)0.008
 Transcranial cerebral oximetry24 417 (15)401 (14)239 (24)16 383 (13)7394 (27)0.001
 SSEP36 417 (23)756 (26)8 (0.8)35 320 (28)333 (1.2)0.900
 Other methods36 780 (23)576 (20)186 (19)30 234 (24)5784 (21)<0.001
Operation technique‡
 TEA direct suture2017 (1.6)64 (2.2)1953 (1.5)
 TEA with patch44 944 (35)1004 (35)43 940 (35)
 Eversion CEA53 149 (41)963 (33)52 186 (41)
 Interposition2478 (1.9)144 (5.0)2334 (1.8)
 Other techniques#27 014 (21)705 (25)26 309 (21)
Intra-arterial shunt use*‡55 681 (35)16 040 (56)54 077 (43)
Intraoperative completion study‡
 Any type116 715 (74)1960 (68)933 (94)88 196 (70)25 626 (92)<0.001
 Imaging technique only88 085 (56)1329 (46)917 (92)60 700 (48)25 139 (91)<0.001
Duration of operation (min), median (interquartile range)80 (60–103)94 (74–122)60 (42–90)86 (68–107)45 (40–60)<0.001
Duration of hospital stay after procedure (days), median (interquartile range)
 All patients5 (3–6)9 (5–16)8 (4–14)5 (4–6)2 (2–5)<0.001
 Asymptomatic patients4 (3–6)9 (5–16)7 (3–14)5 (4–6)2 (2–4)<0.001
 Symptomatic patients5 (4–7)10 (5–16)8 (4–14)5 (4–7)3 (2–6)<0.001
OverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Neurological assessment*
 Pre-procedural161 069 (73)3211 (78)1341 (88)124 088 (71)32 429 (81)<0.001
 Post-procedural138 556 (63)3469 (85)1393 (91)104 419 (60)29 275 (73)<0.001
 Pre- and post-procedural128 510 (58)2914 (71)1289 (85)96 118 (55)28 189 (70)<0.001
Preoperative diagnostic procedures*†‡
 Duplex ultrasonography152 681 (96)2784 (97)702 (71)124 661 (98)24 534 (88)<0.001
 Transcranial Doppler45 833 (29)956 (33)415 (42)34 348 (27)10 114 (36)<0.001
 CT angiography83 861 (53)1899 (66)681 (69)66 739 (53)14 542 (52)<0.001
 MRI angiography74 976 (47)1301 (45)419 (42)60 729 (48)12 527 (45)<0.001
Perioperative antiplatelet medication
 None13 361 (6.0)332 (8.1)148 (9.7)11 577 (6.6)1304 (3.3)<0.001
 ASS monotherapy163 612 (74)3464 (85)477 (31)149 984 (85)9687 (24)<0.001
 Clopidogrel monotherapy5781 (2.6)94 (2.3)53 (3.5)4392 (2.5)1242 (3.1)<0.001
 Other monotherapy1078 (0.5)8 (0.2)33 (2.2)767 (0.4)270 (0.7)<0.001
 Dual antiplatelet medication37 450 (17)201 (4.9)813 (53)8905 (5.1)27 531 (69)0.001
Type of anaesthesia‡
 Local34 775 (27)589 (21)34 186 (27)
 General91 562 (71)2194 (76)89 368 (71)
 Combined§3265 (2.5)97 (3.4)3168 (2.5)
Intra-procedural monitoring‡¶
 Electroencephalography8209 (5.2)149 (5.2)8 (0.8)7903 (6.2)149 (0.5)0.008
 Transcranial cerebral oximetry24 417 (15)401 (14)239 (24)16 383 (13)7394 (27)0.001
 SSEP36 417 (23)756 (26)8 (0.8)35 320 (28)333 (1.2)0.900
 Other methods36 780 (23)576 (20)186 (19)30 234 (24)5784 (21)<0.001
Operation technique‡
 TEA direct suture2017 (1.6)64 (2.2)1953 (1.5)
 TEA with patch44 944 (35)1004 (35)43 940 (35)
 Eversion CEA53 149 (41)963 (33)52 186 (41)
 Interposition2478 (1.9)144 (5.0)2334 (1.8)
 Other techniques#27 014 (21)705 (25)26 309 (21)
Intra-arterial shunt use*‡55 681 (35)16 040 (56)54 077 (43)
Intraoperative completion study‡
 Any type116 715 (74)1960 (68)933 (94)88 196 (70)25 626 (92)<0.001
 Imaging technique only88 085 (56)1329 (46)917 (92)60 700 (48)25 139 (91)<0.001
Duration of operation (min), median (interquartile range)80 (60–103)94 (74–122)60 (42–90)86 (68–107)45 (40–60)<0.001
Duration of hospital stay after procedure (days), median (interquartile range)
 All patients5 (3–6)9 (5–16)8 (4–14)5 (4–6)2 (2–5)<0.001
 Asymptomatic patients4 (3–6)9 (5–16)7 (3–14)5 (4–6)2 (2–4)<0.001
 Symptomatic patients5 (4–7)10 (5–16)8 (4–14)5 (4–7)3 (2–6)<0.001

Values are n (%) unless otherwise indicated. *Yes versus no. †Multiple answers possible. ‡Only available from 2012 to 2016. §Patients who received a combination of local and general anaesthesia were likely to have predominantly undergone conversion from local to general anaesthesia. †,¶Multiple answers possible; information on percentages of subcategories refers to the cohort of patients who received intra-procedural neurophysiological monitoring; other methods include local anaesthesia in combination with the duck squeezing test, transcranial Doppler sonography, and measurement of stump pressure. #Other techniques include, for example, transposition of the carotid bifurcation, as well as procedures documented as ‘other’. OE, outcome event; CEA, carotid endarterectomy; CAS, carotid artery stenting; ASS, Acetylsalicylic acid; SSEP, Somatosensory evoked potential.

Table 2

Perioperative and intraoperative management

OverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Neurological assessment*
 Pre-procedural161 069 (73)3211 (78)1341 (88)124 088 (71)32 429 (81)<0.001
 Post-procedural138 556 (63)3469 (85)1393 (91)104 419 (60)29 275 (73)<0.001
 Pre- and post-procedural128 510 (58)2914 (71)1289 (85)96 118 (55)28 189 (70)<0.001
Preoperative diagnostic procedures*†‡
 Duplex ultrasonography152 681 (96)2784 (97)702 (71)124 661 (98)24 534 (88)<0.001
 Transcranial Doppler45 833 (29)956 (33)415 (42)34 348 (27)10 114 (36)<0.001
 CT angiography83 861 (53)1899 (66)681 (69)66 739 (53)14 542 (52)<0.001
 MRI angiography74 976 (47)1301 (45)419 (42)60 729 (48)12 527 (45)<0.001
Perioperative antiplatelet medication
 None13 361 (6.0)332 (8.1)148 (9.7)11 577 (6.6)1304 (3.3)<0.001
 ASS monotherapy163 612 (74)3464 (85)477 (31)149 984 (85)9687 (24)<0.001
 Clopidogrel monotherapy5781 (2.6)94 (2.3)53 (3.5)4392 (2.5)1242 (3.1)<0.001
 Other monotherapy1078 (0.5)8 (0.2)33 (2.2)767 (0.4)270 (0.7)<0.001
 Dual antiplatelet medication37 450 (17)201 (4.9)813 (53)8905 (5.1)27 531 (69)0.001
Type of anaesthesia‡
 Local34 775 (27)589 (21)34 186 (27)
 General91 562 (71)2194 (76)89 368 (71)
 Combined§3265 (2.5)97 (3.4)3168 (2.5)
Intra-procedural monitoring‡¶
 Electroencephalography8209 (5.2)149 (5.2)8 (0.8)7903 (6.2)149 (0.5)0.008
 Transcranial cerebral oximetry24 417 (15)401 (14)239 (24)16 383 (13)7394 (27)0.001
 SSEP36 417 (23)756 (26)8 (0.8)35 320 (28)333 (1.2)0.900
 Other methods36 780 (23)576 (20)186 (19)30 234 (24)5784 (21)<0.001
Operation technique‡
 TEA direct suture2017 (1.6)64 (2.2)1953 (1.5)
 TEA with patch44 944 (35)1004 (35)43 940 (35)
 Eversion CEA53 149 (41)963 (33)52 186 (41)
 Interposition2478 (1.9)144 (5.0)2334 (1.8)
 Other techniques#27 014 (21)705 (25)26 309 (21)
Intra-arterial shunt use*‡55 681 (35)16 040 (56)54 077 (43)
Intraoperative completion study‡
 Any type116 715 (74)1960 (68)933 (94)88 196 (70)25 626 (92)<0.001
 Imaging technique only88 085 (56)1329 (46)917 (92)60 700 (48)25 139 (91)<0.001
Duration of operation (min), median (interquartile range)80 (60–103)94 (74–122)60 (42–90)86 (68–107)45 (40–60)<0.001
Duration of hospital stay after procedure (days), median (interquartile range)
 All patients5 (3–6)9 (5–16)8 (4–14)5 (4–6)2 (2–5)<0.001
 Asymptomatic patients4 (3–6)9 (5–16)7 (3–14)5 (4–6)2 (2–4)<0.001
 Symptomatic patients5 (4–7)10 (5–16)8 (4–14)5 (4–7)3 (2–6)<0.001
OverallOE occurredOE did not occurP (chi-squared)
CEACASCEACAS
Neurological assessment*
 Pre-procedural161 069 (73)3211 (78)1341 (88)124 088 (71)32 429 (81)<0.001
 Post-procedural138 556 (63)3469 (85)1393 (91)104 419 (60)29 275 (73)<0.001
 Pre- and post-procedural128 510 (58)2914 (71)1289 (85)96 118 (55)28 189 (70)<0.001
Preoperative diagnostic procedures*†‡
 Duplex ultrasonography152 681 (96)2784 (97)702 (71)124 661 (98)24 534 (88)<0.001
 Transcranial Doppler45 833 (29)956 (33)415 (42)34 348 (27)10 114 (36)<0.001
 CT angiography83 861 (53)1899 (66)681 (69)66 739 (53)14 542 (52)<0.001
 MRI angiography74 976 (47)1301 (45)419 (42)60 729 (48)12 527 (45)<0.001
Perioperative antiplatelet medication
 None13 361 (6.0)332 (8.1)148 (9.7)11 577 (6.6)1304 (3.3)<0.001
 ASS monotherapy163 612 (74)3464 (85)477 (31)149 984 (85)9687 (24)<0.001
 Clopidogrel monotherapy5781 (2.6)94 (2.3)53 (3.5)4392 (2.5)1242 (3.1)<0.001
 Other monotherapy1078 (0.5)8 (0.2)33 (2.2)767 (0.4)270 (0.7)<0.001
 Dual antiplatelet medication37 450 (17)201 (4.9)813 (53)8905 (5.1)27 531 (69)0.001
Type of anaesthesia‡
 Local34 775 (27)589 (21)34 186 (27)
 General91 562 (71)2194 (76)89 368 (71)
 Combined§3265 (2.5)97 (3.4)3168 (2.5)
Intra-procedural monitoring‡¶
 Electroencephalography8209 (5.2)149 (5.2)8 (0.8)7903 (6.2)149 (0.5)0.008
 Transcranial cerebral oximetry24 417 (15)401 (14)239 (24)16 383 (13)7394 (27)0.001
 SSEP36 417 (23)756 (26)8 (0.8)35 320 (28)333 (1.2)0.900
 Other methods36 780 (23)576 (20)186 (19)30 234 (24)5784 (21)<0.001
Operation technique‡
 TEA direct suture2017 (1.6)64 (2.2)1953 (1.5)
 TEA with patch44 944 (35)1004 (35)43 940 (35)
 Eversion CEA53 149 (41)963 (33)52 186 (41)
 Interposition2478 (1.9)144 (5.0)2334 (1.8)
 Other techniques#27 014 (21)705 (25)26 309 (21)
Intra-arterial shunt use*‡55 681 (35)16 040 (56)54 077 (43)
Intraoperative completion study‡
 Any type116 715 (74)1960 (68)933 (94)88 196 (70)25 626 (92)<0.001
 Imaging technique only88 085 (56)1329 (46)917 (92)60 700 (48)25 139 (91)<0.001
Duration of operation (min), median (interquartile range)80 (60–103)94 (74–122)60 (42–90)86 (68–107)45 (40–60)<0.001
Duration of hospital stay after procedure (days), median (interquartile range)
 All patients5 (3–6)9 (5–16)8 (4–14)5 (4–6)2 (2–5)<0.001
 Asymptomatic patients4 (3–6)9 (5–16)7 (3–14)5 (4–6)2 (2–4)<0.001
 Symptomatic patients5 (4–7)10 (5–16)8 (4–14)5 (4–7)3 (2–6)<0.001

Values are n (%) unless otherwise indicated. *Yes versus no. †Multiple answers possible. ‡Only available from 2012 to 2016. §Patients who received a combination of local and general anaesthesia were likely to have predominantly undergone conversion from local to general anaesthesia. †,¶Multiple answers possible; information on percentages of subcategories refers to the cohort of patients who received intra-procedural neurophysiological monitoring; other methods include local anaesthesia in combination with the duck squeezing test, transcranial Doppler sonography, and measurement of stump pressure. #Other techniques include, for example, transposition of the carotid bifurcation, as well as procedures documented as ‘other’. OE, outcome event; CEA, carotid endarterectomy; CAS, carotid artery stenting; ASS, Acetylsalicylic acid; SSEP, Somatosensory evoked potential.

Outcomes and interaction effects

A total of 5623 events occurred, which corresponded to an overall raw risk of stroke or death until hospital discharge of 2.5%. The risk of OE was 2.3% and 3.7% in patients who underwent CEA and CAS respectively (Table 3). Patient age was statistically significantly associated with higher OE risk (main effect of age by 10-year steps: adjusted OR 1.21 (95% c.i. 1.17 to 1.26), P < 0.001). The age effect was statistically significantly stronger in patients treated with CAS (interaction effect: adjusted OR 1.29 (95% c.i. 1.20 to 1.38), P < 0.001) (Table 3). Figure 2a illustrates the association between age, treatment type, and risk of OE. Higher annual centre volume (all CEA and CAS procedures) was associated with lower risk of OE (main effect of hospital volume per 1 log point: adjusted OR 0.84 (95% c.i. 0.80 to 0.89), P < 0.001). However, the volume–outcome effect was not different between CEA and CAS (interaction effect: adjusted OR 1.02 (95% c.i. 0.95 to 1.11), P = 0.549). Figure 2b shows the volume–outcome association. Multilevel multivariable regression analysis revealed statistically significant interaction effects for the side of treatment, ASA grade, contralateral degree of stenosis, the time interval between the index event and treatment, and aneurysmal change of the ipsilateral internal carotid artery (Table 3).

Visualized association between the type of treatment, the risk of stroke or death until discharge from hospital, and patient age or annual hospital volume
Fig. 2

Visualized association between the type of treatment, the risk of stroke or death until discharge from hospital, and patient age or annual hospital volume

a Patient age. b Annual hospital volume. Data derived from microsimulation (see the Methods section). Absolute risk of stroke or death until discharge was simulated based on the parameters derived from the multivariable regression models. A microsimulation was necessary because a direct display of data points of individual patients was prohibited for data protection reasons. Carotid endarterectomy = blue and carotid artery stenting = red. CEA, carotid endarterectomy; CAS, carotid artery stenting.

Table 3

Adjusted ORs for the interaction effect between the index clinical variable, treatment type, and outcome

Clinical variableRaw risk (%)Raw relative risk, CAS versus CEAInteraction effect, CAS versus CEA
CEACASRR (95% c.i.)PaOR (95% c.i.)P
Overall cohort2.33.71.61 (1.52,1.70)<0.001
Age (10-year steps)1.29 (1.20,1.38)<0.001*
Centre annual caseload1.02 (0.95,1.11)0.549
Sex
 Male (reference)2.33.51.56 (1.46,1.68)<0.0011.11 (0.97,1.26)0.123
 Female2.33.91.71 (1.55,1.89)<0.001
Side of treatment
 Right2.03.41.74 (1.59,1.90)<0.0011.17 (1.03,1.32)0.011*
 Left (reference)2.63.91.50 (1.39,1.63)<0.001
ASA grade
 I + II1.32.31.83 (1.63,2.06)<0.001Reference
 III2.44.31.76 (1.61,1.91)<0.0011.05 (0.91,1.22)0.495
 IV + V8.218.22.21 (1.94,2.53)<0.0011.35 (1.09,1.65)0.004*
Ipsilateral degree of stenosis†
 Mild (<50%)4.85.21.07 (0.79,1.46)0.6570.75 (0.54,1.05)0.091
 Moderate (50–69%)3.14.21.33 (1.06,1.67)0.0130.89 (0.70,1.15)0.377
 Severe (70–99%)2.13.11.44 (1.35,1.54)<0.001Reference
 Occlusion (100%)9.714.41.49 (1.22,1.82)<0.0010.95 (0.74,1.21)0.657
Contralateral degree of stenosis†
 Mild (<50%)2.13.71.77 (1.65,1.90)<0.0011.15 (0.95,1.38)0.152
 Moderate (50–69%)2.32.91.25 (1.03,1.52)0.0260.80 (0.61,1.05)0.104
 Severe (70–99%)2.64.11.59 (1.35,1.88)<0.001Reference
 Occlusion (100%)4.14.00.98 (0.82,1.18)0.8560.61 (0.47,0.79)<0.001*
Neurological symptoms
 Asymptomatic1.41.71.20 (1.08,1.35)0.001Reference
 Symptomatic
  Amaurosis fugax1.31.30.97 (0.63,1.49)0.8840.72 (0.45,1.16)0.182
  TIA2.43.51.47 (1.20,1.81)<0.0011.04 (0.81,1.34)0.734
  Stroke (minor/major/NA)3.54.51.29 (1.15,1.46)<0.0011.02 (0.84,1.23)0.866
  Other elective symptoms2.92.80.95 (0.62,1.46)0.8240.79 (0.49,1.27)0.330
  cTIA/SIE6.810.71.57 (1.38,1.79)<0.0011.09 (0.88,1.34)0.427
  Other emergency symptoms5.68.01.42 (1.21,1.66)<0.0011.03 (0.82,1.28)0.819
Time interval (days)‡
 0–24.16.51.59 (1.28,1.99)<0.0011.71 (1.21,2.43)0.003*
 3–72.83.81.35 (1.14,1.61)<0.0011.38 (0.87,2.19)0.170
 8–143.03.00.99 (0.77,1.28)0.962Reference
 15–1802.53.51.42 (1.18,1.72)<0.0011.50 (0.94,2.39)0.090
Morphological characteristics
 Ulcerated plaque2.95.61.94 (1.57,2.39)<0.0011.15 (0.91,1.46)0.235
 Aneurysmal change§7.15.90.83 (0.54,1.28)0.3960.49 (0.31,0.78)0.002*
 Coiling3.99.32.37 (1.34,4.22)0.0031.38 (0.74,2.56)0.311
 Multiple lesions6.28.51.38 (1.15,1.65)<0.0010.86 (0.70,1.06)0.169
Clinical variableRaw risk (%)Raw relative risk, CAS versus CEAInteraction effect, CAS versus CEA
CEACASRR (95% c.i.)PaOR (95% c.i.)P
Overall cohort2.33.71.61 (1.52,1.70)<0.001
Age (10-year steps)1.29 (1.20,1.38)<0.001*
Centre annual caseload1.02 (0.95,1.11)0.549
Sex
 Male (reference)2.33.51.56 (1.46,1.68)<0.0011.11 (0.97,1.26)0.123
 Female2.33.91.71 (1.55,1.89)<0.001
Side of treatment
 Right2.03.41.74 (1.59,1.90)<0.0011.17 (1.03,1.32)0.011*
 Left (reference)2.63.91.50 (1.39,1.63)<0.001
ASA grade
 I + II1.32.31.83 (1.63,2.06)<0.001Reference
 III2.44.31.76 (1.61,1.91)<0.0011.05 (0.91,1.22)0.495
 IV + V8.218.22.21 (1.94,2.53)<0.0011.35 (1.09,1.65)0.004*
Ipsilateral degree of stenosis†
 Mild (<50%)4.85.21.07 (0.79,1.46)0.6570.75 (0.54,1.05)0.091
 Moderate (50–69%)3.14.21.33 (1.06,1.67)0.0130.89 (0.70,1.15)0.377
 Severe (70–99%)2.13.11.44 (1.35,1.54)<0.001Reference
 Occlusion (100%)9.714.41.49 (1.22,1.82)<0.0010.95 (0.74,1.21)0.657
Contralateral degree of stenosis†
 Mild (<50%)2.13.71.77 (1.65,1.90)<0.0011.15 (0.95,1.38)0.152
 Moderate (50–69%)2.32.91.25 (1.03,1.52)0.0260.80 (0.61,1.05)0.104
 Severe (70–99%)2.64.11.59 (1.35,1.88)<0.001Reference
 Occlusion (100%)4.14.00.98 (0.82,1.18)0.8560.61 (0.47,0.79)<0.001*
Neurological symptoms
 Asymptomatic1.41.71.20 (1.08,1.35)0.001Reference
 Symptomatic
  Amaurosis fugax1.31.30.97 (0.63,1.49)0.8840.72 (0.45,1.16)0.182
  TIA2.43.51.47 (1.20,1.81)<0.0011.04 (0.81,1.34)0.734
  Stroke (minor/major/NA)3.54.51.29 (1.15,1.46)<0.0011.02 (0.84,1.23)0.866
  Other elective symptoms2.92.80.95 (0.62,1.46)0.8240.79 (0.49,1.27)0.330
  cTIA/SIE6.810.71.57 (1.38,1.79)<0.0011.09 (0.88,1.34)0.427
  Other emergency symptoms5.68.01.42 (1.21,1.66)<0.0011.03 (0.82,1.28)0.819
Time interval (days)‡
 0–24.16.51.59 (1.28,1.99)<0.0011.71 (1.21,2.43)0.003*
 3–72.83.81.35 (1.14,1.61)<0.0011.38 (0.87,2.19)0.170
 8–143.03.00.99 (0.77,1.28)0.962Reference
 15–1802.53.51.42 (1.18,1.72)<0.0011.50 (0.94,2.39)0.090
Morphological characteristics
 Ulcerated plaque2.95.61.94 (1.57,2.39)<0.0011.15 (0.91,1.46)0.235
 Aneurysmal change§7.15.90.83 (0.54,1.28)0.3960.49 (0.31,0.78)0.002*
 Coiling3.99.32.37 (1.34,4.22)0.0031.38 (0.74,2.56)0.311
 Multiple lesions6.28.51.38 (1.15,1.65)<0.0010.86 (0.70,1.06)0.169

Raw risks for age and volume are shown in Fig. 2. *Statistically significant. †Degree of stenosis is in accordance with the North American Symptomatic Carotid Endarterectomy Trial (NASCET) standard. ‡Only available for symptomatic patients treated electively. §Aneurysmal change in addition to the atherosclerotic stenosis. CAS, carotid artery stenting; CEA, carotid endarterectomy; RR, relative risk; aOR, adjusted OR (statistical interaction effect between the index variable, treatment (CAS versus CEA), and the risk of any stroke or death until discharge (primary outcome event)); TIA, transient ischaemic attack; NA, information not available; cTIA, crescendo transient ischaemic attack; SIE, stroke-in-evolution.

Table 3

Adjusted ORs for the interaction effect between the index clinical variable, treatment type, and outcome

Clinical variableRaw risk (%)Raw relative risk, CAS versus CEAInteraction effect, CAS versus CEA
CEACASRR (95% c.i.)PaOR (95% c.i.)P
Overall cohort2.33.71.61 (1.52,1.70)<0.001
Age (10-year steps)1.29 (1.20,1.38)<0.001*
Centre annual caseload1.02 (0.95,1.11)0.549
Sex
 Male (reference)2.33.51.56 (1.46,1.68)<0.0011.11 (0.97,1.26)0.123
 Female2.33.91.71 (1.55,1.89)<0.001
Side of treatment
 Right2.03.41.74 (1.59,1.90)<0.0011.17 (1.03,1.32)0.011*
 Left (reference)2.63.91.50 (1.39,1.63)<0.001
ASA grade
 I + II1.32.31.83 (1.63,2.06)<0.001Reference
 III2.44.31.76 (1.61,1.91)<0.0011.05 (0.91,1.22)0.495
 IV + V8.218.22.21 (1.94,2.53)<0.0011.35 (1.09,1.65)0.004*
Ipsilateral degree of stenosis†
 Mild (<50%)4.85.21.07 (0.79,1.46)0.6570.75 (0.54,1.05)0.091
 Moderate (50–69%)3.14.21.33 (1.06,1.67)0.0130.89 (0.70,1.15)0.377
 Severe (70–99%)2.13.11.44 (1.35,1.54)<0.001Reference
 Occlusion (100%)9.714.41.49 (1.22,1.82)<0.0010.95 (0.74,1.21)0.657
Contralateral degree of stenosis†
 Mild (<50%)2.13.71.77 (1.65,1.90)<0.0011.15 (0.95,1.38)0.152
 Moderate (50–69%)2.32.91.25 (1.03,1.52)0.0260.80 (0.61,1.05)0.104
 Severe (70–99%)2.64.11.59 (1.35,1.88)<0.001Reference
 Occlusion (100%)4.14.00.98 (0.82,1.18)0.8560.61 (0.47,0.79)<0.001*
Neurological symptoms
 Asymptomatic1.41.71.20 (1.08,1.35)0.001Reference
 Symptomatic
  Amaurosis fugax1.31.30.97 (0.63,1.49)0.8840.72 (0.45,1.16)0.182
  TIA2.43.51.47 (1.20,1.81)<0.0011.04 (0.81,1.34)0.734
  Stroke (minor/major/NA)3.54.51.29 (1.15,1.46)<0.0011.02 (0.84,1.23)0.866
  Other elective symptoms2.92.80.95 (0.62,1.46)0.8240.79 (0.49,1.27)0.330
  cTIA/SIE6.810.71.57 (1.38,1.79)<0.0011.09 (0.88,1.34)0.427
  Other emergency symptoms5.68.01.42 (1.21,1.66)<0.0011.03 (0.82,1.28)0.819
Time interval (days)‡
 0–24.16.51.59 (1.28,1.99)<0.0011.71 (1.21,2.43)0.003*
 3–72.83.81.35 (1.14,1.61)<0.0011.38 (0.87,2.19)0.170
 8–143.03.00.99 (0.77,1.28)0.962Reference
 15–1802.53.51.42 (1.18,1.72)<0.0011.50 (0.94,2.39)0.090
Morphological characteristics
 Ulcerated plaque2.95.61.94 (1.57,2.39)<0.0011.15 (0.91,1.46)0.235
 Aneurysmal change§7.15.90.83 (0.54,1.28)0.3960.49 (0.31,0.78)0.002*
 Coiling3.99.32.37 (1.34,4.22)0.0031.38 (0.74,2.56)0.311
 Multiple lesions6.28.51.38 (1.15,1.65)<0.0010.86 (0.70,1.06)0.169
Clinical variableRaw risk (%)Raw relative risk, CAS versus CEAInteraction effect, CAS versus CEA
CEACASRR (95% c.i.)PaOR (95% c.i.)P
Overall cohort2.33.71.61 (1.52,1.70)<0.001
Age (10-year steps)1.29 (1.20,1.38)<0.001*
Centre annual caseload1.02 (0.95,1.11)0.549
Sex
 Male (reference)2.33.51.56 (1.46,1.68)<0.0011.11 (0.97,1.26)0.123
 Female2.33.91.71 (1.55,1.89)<0.001
Side of treatment
 Right2.03.41.74 (1.59,1.90)<0.0011.17 (1.03,1.32)0.011*
 Left (reference)2.63.91.50 (1.39,1.63)<0.001
ASA grade
 I + II1.32.31.83 (1.63,2.06)<0.001Reference
 III2.44.31.76 (1.61,1.91)<0.0011.05 (0.91,1.22)0.495
 IV + V8.218.22.21 (1.94,2.53)<0.0011.35 (1.09,1.65)0.004*
Ipsilateral degree of stenosis†
 Mild (<50%)4.85.21.07 (0.79,1.46)0.6570.75 (0.54,1.05)0.091
 Moderate (50–69%)3.14.21.33 (1.06,1.67)0.0130.89 (0.70,1.15)0.377
 Severe (70–99%)2.13.11.44 (1.35,1.54)<0.001Reference
 Occlusion (100%)9.714.41.49 (1.22,1.82)<0.0010.95 (0.74,1.21)0.657
Contralateral degree of stenosis†
 Mild (<50%)2.13.71.77 (1.65,1.90)<0.0011.15 (0.95,1.38)0.152
 Moderate (50–69%)2.32.91.25 (1.03,1.52)0.0260.80 (0.61,1.05)0.104
 Severe (70–99%)2.64.11.59 (1.35,1.88)<0.001Reference
 Occlusion (100%)4.14.00.98 (0.82,1.18)0.8560.61 (0.47,0.79)<0.001*
Neurological symptoms
 Asymptomatic1.41.71.20 (1.08,1.35)0.001Reference
 Symptomatic
  Amaurosis fugax1.31.30.97 (0.63,1.49)0.8840.72 (0.45,1.16)0.182
  TIA2.43.51.47 (1.20,1.81)<0.0011.04 (0.81,1.34)0.734
  Stroke (minor/major/NA)3.54.51.29 (1.15,1.46)<0.0011.02 (0.84,1.23)0.866
  Other elective symptoms2.92.80.95 (0.62,1.46)0.8240.79 (0.49,1.27)0.330
  cTIA/SIE6.810.71.57 (1.38,1.79)<0.0011.09 (0.88,1.34)0.427
  Other emergency symptoms5.68.01.42 (1.21,1.66)<0.0011.03 (0.82,1.28)0.819
Time interval (days)‡
 0–24.16.51.59 (1.28,1.99)<0.0011.71 (1.21,2.43)0.003*
 3–72.83.81.35 (1.14,1.61)<0.0011.38 (0.87,2.19)0.170
 8–143.03.00.99 (0.77,1.28)0.962Reference
 15–1802.53.51.42 (1.18,1.72)<0.0011.50 (0.94,2.39)0.090
Morphological characteristics
 Ulcerated plaque2.95.61.94 (1.57,2.39)<0.0011.15 (0.91,1.46)0.235
 Aneurysmal change§7.15.90.83 (0.54,1.28)0.3960.49 (0.31,0.78)0.002*
 Coiling3.99.32.37 (1.34,4.22)0.0031.38 (0.74,2.56)0.311
 Multiple lesions6.28.51.38 (1.15,1.65)<0.0010.86 (0.70,1.06)0.169

Raw risks for age and volume are shown in Fig. 2. *Statistically significant. †Degree of stenosis is in accordance with the North American Symptomatic Carotid Endarterectomy Trial (NASCET) standard. ‡Only available for symptomatic patients treated electively. §Aneurysmal change in addition to the atherosclerotic stenosis. CAS, carotid artery stenting; CEA, carotid endarterectomy; RR, relative risk; aOR, adjusted OR (statistical interaction effect between the index variable, treatment (CAS versus CEA), and the risk of any stroke or death until discharge (primary outcome event)); TIA, transient ischaemic attack; NA, information not available; cTIA, crescendo transient ischaemic attack; SIE, stroke-in-evolution.

Discussion

This analysis of nationwide real-world data reveals the generally higher in-hospital risk of stroke or death after CAS. Therefore, this analysis highlights that CEA is the treatment of choice, as recommended by current guidelines. Based on this study, CAS may be particularly disadvantageous in older patients, in patients with right-sided stenosis, and in symptomatic patients treated within the first 2 days after the index event. It may be equivalent to CEA in patients with contralateral occlusion, as well as symptomatic patients treated in the second week after the index event. Greater than 40 000 CAS procedures were performed from 2012 to 2018, of which 21 000 were in asymptomatic patients, despite the recommendations in the German–Austrian guideline (first published in 2012). The reasons for method selection cannot be substantiated based on the available data, but widespread compliance with the guideline recommendations still appears inadequate in Germany. This should encourage national educational measures to improve guideline-compliant care.

The overall risk of OE was generally higher in CAS compared with CEA (3.7% versus 2.3% respectively), which corresponds well with other reports4,25 and a comprehensive Cochrane systematic review26. The latter meta-analysis included 5396 patients from 10 RCTs. The risk of any stroke or death within 30 days in asymptomatic patients in this Cochrane review was 1.4% for CEA and 2.5% for CAS (OR 1.72 (95% c.i. 1.00 to 2.97)). In symptomatic patients, these figures were 4.4% versus 7.2% respectively (OR 1.70 (95% c.i. 1.31 to 2.19)). In comparison, the specific risks for CEA and CAS in this study were 1.4% and 1.7% respectively in asymptomatic patients and 3.3% and 5.7% respectively in symptomatic patients (elective or emergency treatment). These values are generally somewhat lower compared with the Cochrane review cited above and other studies. The German quality assurance data are exclusively inpatient data, whereas the risks reported in RCTs are usually associated with an interval of up to 30 days; consequently, the risks determined in this study are probably too low, with the actual risks being higher. Information bias can be assumed, as statutory quality assurance in Germany relates exclusively to the inpatient sector, with no association with other social data to date. The different duration of hospital stay needs to be considered, which is statistically significantly shorter for CAS (2 days) than for CEA (5 days). This results in a shorter interval ‘under observation’ for CAS in which an OE could be recorded for quality assurance purposes. Therefore, the actual outcome risks may be even higher after CAS compared with CEA and the size of the differential effects found in this study is probably underestimated.

The association between age and the risk of OE was stronger in CAS compared with CEA (Fig. 2a). The different slopes for CEA and CAS can be used to identify the effect modification. This indicates that, the older the patients, the lower the relative risk of CEA compared with CAS under otherwise identical conditions. These results are congruent with earlier publications from Germany16,17, an individual patient meta-analysis of the Carotid Stenting Trialists’ Collaboration (CSTC; data from the International Carotid Stenting Study (ICSS), the Carotid Revascularization Endarterectomy versus Stent Trial (CREST), the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial, and the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial)27,28, and a systematic review of international observational studies29. The aforementioned CSTC meta-analysis identified age as a statistically significant effect modifier, but all other subgroups analysed demonstrated no evidence of effect modification. These divergent results may be due to several variations between the CSTC data and the mandatory nationwide German carotid database. In particular, the CSTC included considerably fewer patients (3433 versus 221 282), only symptomatic patients, only patients who were eligible for both procedures, only patients in participating centres, only patients who consented to study participation, and only patients who met all inclusion criteria, and participating centres and physicians had to meet all minimum requirements for participation. Conversely, the CSTC included patients who were randomized (but only for the CEA–CAS head-to-head comparison), patients who were from different countries, and, most importantly, patients who were prospectively documented, resulting in very low information bias. Notably, the external validity of RCTs is heterogeneous and may vary from clinical practice, for example concerning age, co-morbidities and medication, as analysed in detail by Kallmayer et al.30. A higher risk in older patients could be caused by increasing vascular calcification with age, especially in patients with calcification of the access routes to the carotid artery16,17. A retrospective analysis of the Vascular Quality Initiative database that included 11 342 patients who underwent transfemoral CAS or transcarotid artery revascularization (TCAR) supported this notion; this study revealed that marked carotid artery calcification was associated with worse outcomes in patients who underwent transfemoral CAS, whereas this was not the case with TCAR31. Additionally, the formation of unfavourable aortic arch anatomy during ageing may cause a higher risk in old patients who undergo CAS26,32. Further, the negative effects of an unfavourable or longer access route could cause a higher risk of right-sided stenosis in CAS than in CEA, as the present study reveals. A higher risk of right-sided CAS was also found in the systematic review by Touzé et al.29, which included greater than 30 000 patients from 12 studies.

The risk of OE was comparable in both CEA (4.1%) and CAS (4.0%) in the subgroup of patients with contralateral carotid occlusion (CCO). In contrast, Krawisz et al.33 analysed 58 423 patients from the USA and reported that the risk of in-hospital stroke or death in patients with CCO was 3.0% for CEA and 1.9% for CAS. These results are congruent with the findings of Touzé et al.29, demonstrating that CEA was statistically significantly associated with a higher risk of stroke or death in patients with CCO (risk ratio 1.56 (95% c.i. 1.31 to 1.86)), whereas CAS exhibited no increased risk in patients with CCO. Additionally, contralateral occlusion was determined to be a statistically significant predictor of the 30-day stroke or death rate after CEA and was thus included in the Ontario Carotid Endarterectomy Registry risk model34. A large external validation study identified the Ontario Carotid Endarterectomy Registry risk model as providing the most reliable predictions of stroke or death rates after CEA7; unfortunately, the study did not conduct a direct comparison with CAS. In summary, more consideration may be given to CAS in the presence of a CCO.

A comprehensive review of 71 studies including greater than 230 000 symptomatic patients summarized that early CEA within 2 or up to 7 days after the index event was safer than transfemoral CAS regarding the timing of treatment35. This is congruent with the results of the present study and an earlier secondary data analysis of the German statutory quality assurance database19. The present analysis considers CAS to be equivalent only in the second week after the index event, and otherwise inferior to CEA, especially in the first 2 days after the index event. In summary, the current real-world data support the recommendations of the guidelines, including those of the European Society for Vascular Surgery (ESVS): patients who are undergoing revascularization within the first 14 days after the onset of symptoms are recommended to undergo CEA, rather than carotid stenting2.

A detailed discussion of the limitations can be found in the Supplementary material and elsewhere10–13,15–21,36–39. In summary, this is a secondary data analysis and thus all difficulties associated with observational studies using routine data must be considered. This is a retrospective study with the observation interval only covering the inpatient stay. All information in the database is self-reported, but the reporting of data on all CEA and CAS procedures was mandatory and required by law in a standardized manner for all of Germany. Only the variables available in the mandatory documentation form could be analysed; thus, risk adjustment was limited and residual confounding could not be excluded.

Funding

The present analysis was a pre-planned substudy of the ISAR-IQ project (Integration and Spatial Analysis of Regional, site-specific, and patient-level factors for Improving the Quality of treatment for carotid artery stenosis) that was funded by Germany’s Federal Joint Committee Innovation Fund (G-BA Innovationsfonds, 01VSF19016 ISAR-IQ).

Acknowledgements

The authors would like to thank Dr Eva Knipfer, MHBA, Mrs Lan Zang, MD, and Dr Stefan Saicic, MD, all from the Department for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich. Additionally, the authors thank Prof. Volker Schmid, PhD, from the Department of Statistics, Ludwig-Maximilians-University of Munich. Furthermore, the authors thank Thomas Lang, MSc, Michael Salvermoser, MSc, Joana Huber, MSc, Sofie Lückerath, MD, and Simon Heuberger, PhD, all former employees of the Department for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich. Finally, the authors thank Peter Hermanek, Julian Böhm, and Rebecca Moser, all from the Landesarbeitsgemeinschaft zur datengestützten, einrichtungsübergreifenden Qualitätssicherung in Bayern (LAG Bayern), and the employees from the IQTIG, for their valuable support regarding data extraction.

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS online.

Data availability

The datasets analysed during the current study are available on request from the IQTIG, (https://iqtig.org/qs-verfahren-uebersicht/sekundaere-datennutzung/).

Author contributions

Andreas Kuehnl (Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing), Christoph Knappich (Conceptualization, Data curation, Investigation, Supervision, Writing—review & editing), Felix Kirchhoff (Data curation, Validation, Writing—review & editing), Bianca Bohmann (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Writing—review & editing), Vanessa Lohe (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing—review & editing), Shamsun Naher (Data curation, Formal analysis, Investigation, Methodology, Validation, Writing—review & editing), Hans-Henning Eckstein (Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing—review & editing), and Michael Kallmayer (Conceptualization, Investigation, Project administration, Resources, Supervision, Validation, Writing—original draft, Writing—review & editing)

References

1

Eckstein
 
HH
,
Kuhnl
 
A
,
Berkefeld
 
J
,
Lawall
 
H
,
Storck
 
M
,
Sander
 
D
.
Diagnosis, treatment and follow-up in extracranial carotid stenosis
.
Dtsch Arztebl Int
 
2020
;
117
:
801
807

2

Naylor
 
R
,
Rantner
 
B
,
Ancetti
 
S
,
de Borst
 
GJ
,
De Carlo
 
M
,
Halliday
 
A
 et al.  
Editor’s Choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease
.
Eur J Vasc Endovasc Surg
 
2023
;
65
:
7
111

3

AbuRahma
 
AF
,
Avgerinos
 
ED
,
Chang
 
RW
,
Darling
 
RC
 III
,
Duncan
 
AA
,
Forbes
 
TL
 et al.  
Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease
.
J Vasc Surg
 
2022
;
75
:
4S
22S

4

Bogiatzi
 
C
,
Azarpazhooh
 
MR
,
Spence
 
JD
.
Choosing the right therapy for a patient with asymptomatic carotid stenosis
.
Expert Rev Cardiovasc Ther
 
2020
;
18
:
53
63

5

Aboyans
 
V
,
Ricco
 
JB
,
Bartelink
 
MEL
,
Bjorck
 
M
,
Brodmann
 
M
,
Cohnert
 
T
 et al.  
2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries
.
Eur Heart J
 
2018
;
39
:
763
816

6

Dakour-Aridi
 
H
,
Faateh
 
M
,
Kuo
 
PL
,
Zarkowsky
 
DS
,
Beck
 
A
,
Malas
 
MB
.
The Vascular Quality Initiative 30-day stroke/death risk score calculator after transfemoral carotid artery stenting
.
J Vasc Surg
 
2020
;
71
:
526
534

7

Poorthuis
 
MHF
,
Herings
 
RAR
,
Dansey
 
K
,
Damen
 
JAA
,
Greving
 
JP
,
Schermerhorn
 
ML
 et al.  
External validation of risk prediction models to improve selection of patients for carotid endarterectomy
.
Stroke
 
2022
;
53
:
87
99

8

Swart
 
E
,
Gothe
 
H
,
Geyer
 
S
,
Jaunzeme
 
J
,
Maier
 
B
,
Grobe
 
TG
 et al.  
[Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations]
.
Gesundheitswesen
 
2015
;
77
:
120
126

9

Benchimol
 
EI
,
Smeeth
 
L
,
Guttmann
 
A
,
Harron
 
K
,
Hemkens
 
LG
,
Moher
 
D
 et al.  
[The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement]
.
Z Evid Fortbild Qual Gesundhwes
 
2016
;
115–116
:
33
48

10

Eckstein
 
HH
,
Tsantilas
 
P
,
Kuhnl
 
A
,
Haller
 
B
,
Breitkreuz
 
T
,
Zimmermann
 
A
 et al.  
Surgical and endovascular treatment of extracranial carotid stenosis
.
Dtsch Arztebl Int
 
2017
;
114
:
729
736

11

Knappich
 
C
,
Kuehnl
 
A
,
Tsantilas
 
P
,
Schmid
 
S
,
Breitkreuz
 
T
,
Kallmayer
 
M
 et al.  
The use of embolic protection devices is associated with a lower stroke and death rate after carotid stenting
.
JACC Cardiovasc Interv
 
2017
;
10
:
1257
1265

12

Knappich
 
C
,
Kuehnl
 
A
,
Tsantilas
 
P
,
Schmid
 
S
,
Breitkreuz
 
T
,
Kallmayer
 
M
 et al.  
Intraoperative completion studies, local anesthesia, and antiplatelet medication are associated with lower risk in carotid endarterectomy
.
Stroke
 
2017
;
48
:
955
962

13

Knappich
 
C
,
Kuehnl
 
A
,
Tsantilas
 
P
,
Schmid
 
S
,
Breitkreuz
 
T
,
Kallmayer
 
M
 et al.  
Patient characteristics and in-hospital outcomes of emergency carotid endarterectomy and carotid stenting after stroke in evolution
.
J Vasc Surg
 
2018
;
68
:
436
444.e6

14

Kuehnl
 
A
,
Salvermoser
 
M
,
Knipfer
 
E
,
Zimmermann
 
A
,
Schmid
 
V
,
Eckstein
 
HH
.
Regional frequency variation of revascularization procedures for carotid stenosis in Germany: secondary data analysis of DRG data from 2012 to 2014
.
Gefasschirurgie
 
2018
;
23
(Suppl 2)
:
56
65

15

Kuehnl
 
A
,
Tsantilas
 
P
,
Knappich
 
C
,
Schmid
 
S
,
Konig
 
T
,
Breitkreuz
 
T
 et al.  
Significant association of annual hospital volume with the risk of inhospital stroke or death following carotid endarterectomy but likely not after carotid stenting: secondary data analysis of the statutory German carotid quality assurance database
.
Circ Cardiovasc Interv
 
2016
;
9
:
e004171

16

Schmid
 
S
,
Tsantilas
 
P
,
Knappich
 
C
,
Kallmayer
 
M
,
Breitkreuz
 
T
,
Zimmermann
 
A
 et al.  
Age but not sex is associated with higher risk of in-hospital stroke or death after carotid artery stenting in symptomatic and asymptomatic carotid stenosis
.
J Vasc Surg
 
2019
;
69
:
1090
1101.e3

17

Schmid
 
S
,
Tsantilas
 
P
,
Knappich
 
C
,
Kallmayer
 
M
,
Konig
 
T
,
Breitkreuz
 
T
 et al.  
Risk of inhospital stroke or death is associated with age but not sex in patients treated with carotid endarterectomy for asymptomatic or symptomatic stenosis in routine practice: secondary data analysis of the nationwide German statutory quality assurance database from 2009 to 2014
.
J Am Heart Assoc
 
2017
;
6
:
e004764

18

Tsantilas
 
P
,
Knappich
 
C
,
Schmid
 
S
,
Kallmayer
 
M
,
Breitkreuz
 
T
,
Zimmermann
 
A
 et al.  
Last neurologic event is associated with risk of in-hospital stroke or death after carotid endarterectomy or carotid artery stenting: secondary data analysis of the German statutory quality assurance database
.
J Vasc Surg
 
2018
;
70
:
1488
1498

19

Tsantilas
 
P
,
Kuehnl
 
A
,
Kallmayer
 
M
,
Knappich
 
C
,
Schmid
 
S
,
Breitkreuz
 
T
 et al.  
Risk of stroke or death is associated with the timing of carotid artery stenting for symptomatic carotid stenosis: a secondary data analysis of the German statutory quality assurance database
.
J Am Heart Assoc
 
2018
;
7
:
e007983

20

Tsantilas
 
P
,
Kuehnl
 
A
,
Konig
 
T
,
Breitkreuz
 
T
,
Kallmayer
 
M
,
Knappich
 
C
 et al.  
Short time interval between neurologic event and carotid surgery is not associated with an increased procedural risk
.
Stroke
 
2016
;
47
:
2783
2790

21

Zimmermann
 
A
,
Knappich
 
C
,
Tsantilas
 
P
,
Kallmayer
 
M
,
Schmid
 
S
,
Breitkreuz
 
T
 et al.  
Different perioperative antiplatelet therapies for patients treated with carotid endarterectomy in routine practice
.
J Vasc Surg
 
2018
;
68
:
1753
1763

22

Li
 
B
,
Lingsma
 
HF
,
Steyerberg
 
EW
,
Lesaffre
 
E
.
Logistic random effects regression models: a comparison of statistical packages for binary and ordinal outcomes
.
BMC Med Res Methodol
 
2011
;
11
:
77

23

Ntani
 
G
,
Inskip
 
H
,
Osmond
 
C
,
Coggon
 
D
.
Consequences of ignoring clustering in linear regression
.
BMC Med Res Methodol
 
2021
;
21
:
139

24

Urbach
 
DR
,
Austin
 
PC
.
Conventional models overestimate the statistical significance of volume–outcome associations, compared with multilevel models
.
J Clin Epidemiol
 
2005
;
58
:
391
400

25

Saratzis
 
A
,
Naylor
 
R
.
30 day outcomes after carotid interventions: an updated meta-analysis of randomised controlled trials in asymptomatic patients
.
Eur J Vasc Endovasc Surg
 
2022
;
63
:
157
158

26

Muller
 
MD
,
Lyrer
 
P
,
Brown
 
MM
,
Bonati
 
LH
.
Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis
.
Cochrane Database Syst Rev
 
2020
;
(2)
CD000515

27

Carotid Stenting Trialists’ Collaboration
.
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data
.
Lancet
 
2010
;
376
:
1062
1073

28

Howard
 
G
,
Roubin
 
GS
,
Jansen
 
O
,
Hendrikse
 
J
,
Halliday
 
A
,
Fraedrich
 
G
 et al.  
Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials
.
Lancet
 
2016
;
387
:
1305
1311

29

Touzé
 
E
,
Trinquart
 
L
,
Felgueiras
 
R
,
Rerkasem
 
K
,
Bonati
 
LH
,
Meliksetyan
 
G
 et al.  
A clinical rule (sex, contralateral occlusion, age, and restenosis) to select patients for stenting versus carotid endarterectomy: systematic review of observational studies with validation in randomized trials
.
Stroke
 
2013
;
44
:
3394
3400

30

Kallmayer
 
MA
,
Knappich
 
C
,
Karlas
 
A
,
Trenner
 
M
,
Kuehnl
 
A
,
Eckstein
 
HH
.
External validity of randomised controlled trials on carotid revascularisation: trial populations may not always reflect patients in clinical practice
.
Eur J Vasc Endovasc Surg
 
2022
;
64
:
452
460

31

Elsayed
 
N
,
Yei
 
KS
,
Naazie
 
I
,
Goodney
 
P
,
Clouse
 
WD
,
Malas
 
M
.
The impact of carotid lesion calcification on outcomes of carotid artery stenting
.
J Vasc Surg
 
2022
;
75
:
921
929

32

Dumont
 
TM
,
Mokin
 
M
,
Wach
 
MM
,
Drummond
 
PS
,
Siddiqui
 
AH
,
Levy
 
EI
 et al.  
Understanding risk factors for perioperative ischemic events with carotid stenting: is patient age over 80 years or is unfavorable arch anatomy to blame?
 
J Neurointerv Surg
 
2014
;
6
:
219
224

33

Krawisz
 
AK
,
Rosenfield
 
K
,
White
 
CJ
,
Jaff
 
MR
,
Campbell
 
J
,
Kennedy
 
K
 et al.  
Clinical impact of contralateral carotid occlusion in patients undergoing carotid artery revascularization
.
J Am Coll Cardiol
 
2021
;
77
:
835
844

34

Tu
 
JV
,
Wang
 
H
,
Bowyer
 
B
,
Green
 
L
,
Fang
 
J
,
Kucey
 
D
 et al.  
Risk factors for death or stroke after carotid endarterectomy: observations from the Ontario Carotid Endarterectomy Registry
.
Stroke
 
2003
;
34
:
2568
2573

35

Coelho
 
A
,
Peixoto
 
J
,
Mansilha
 
A
,
Naylor
 
AR
,
de Borst
 
GJ
.
Editor’s Choice—Timing of carotid intervention in symptomatic carotid artery stenosis: a systematic review and meta-analysis
.
Eur J Vasc Endovasc Surg
 
2022
;
63
:
3
23

36

Chen
 
W
,
Shi
 
J
,
Qian
 
L
,
Azen
 
SP
.
Comparison of robustness to outliers between robust Poisson models and log-binomial models when estimating relative risks for common binary outcomes: a simulation study
.
BMC Med Res Methodol
 
2014
;
14
:
82

37

Davies
 
HT
,
Crombie
 
IK
,
Tavakoli
 
M
.
When can odds ratios mislead?
 
BMJ
 
1998
;
316
:
989
991

38

Diaz-Quijano
 
FA
.
A simple method for estimating relative risk using logistic regression
.
BMC Med Res Methodol
 
2012
;
12
:
14

39

Knappich
 
C
,
Tsantilas
 
P
,
Salvermoser
 
M
,
Schmid
 
S
,
Kallmayer
 
M
,
Trenner
 
M
 et al.  
Editor’s Choice—Distribution of care and hospital incidence of carotid endarterectomy and carotid artery stenting: a secondary analysis of German hospital episode data
.
Eur J Vasc Endovasc Surg
 
2021
;
62
:
167
176

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

Supplementary data